Clinical Trials Directory

Trials / Completed

CompletedNCT01639482

Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram

Status
Completed
Phase
Study type
Observational
Enrollment
60 (actual)
Sponsor
Massachusetts General Hospital · Academic / Other
Sex
All
Age
18 Years – 64 Years
Healthy volunteers
Not accepted

Summary

Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).

Detailed description

Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET). The following hypothesis will be tested: Antidepressant response or remission in depressed BPD patients will be associated with changes in cortical (prefrontal, parietal, premotor) and paralimbic (hippocampus, anterior cingulate, subgenual cingulate, posterior cingulate, and anterior insula) regions, consistent with SRI antidepressant response in unipolar depressed patients.

Conditions

Timeline

Start date
2010-04-01
Primary completion
2013-12-01
Completion
2013-12-01
First posted
2012-07-12
Last updated
2019-03-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01639482. Inclusion in this directory is not an endorsement.